17 research outputs found
Chemometric Approach in Quantification of Structural Identity/Similarity of Proteins in Biopharmaceuticals
Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation
A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages
An integrated process combining the reaction and purification of PEGylated proteins
A downstream process combining PEGylation reaction and the use of enzyme conjugates acting as phase-forming components of aqueous biphasic systems (ABS) is proposed here. In this approach, citrate buffer (pH = 7.0) was used simultaneously to stop the reaction (avoiding the use of hydroxylamine) and as a phase forming agent inducing the phase separation of the PEGylated proteins. The partition of the bioconjugates was assessed using two model enzymes of small size [cytochrome c (Cyt-c) and lysozyme (LYS)], and two of large size [l-asparaginase (ASNase) and catalase (CAT)] as well as reactive PEG of 5, 10, 20 and 40 kDa. The effect of the reaction time on the PEGylation and recovery steps was also evaluated. All reactive PEGs allowed high selectivity in the separation of PEGylated proteins from native proteins (S > 100). A positive effect in terms of selectivity was found for longer reaction times. It allowed greater amounts of PEGylated proteins, with an increase of the PEG-protein rich-phase volume (top phase), allowing 100% of recovery of PEGylated proteins. More selective systems were obtained for Cyt-c and LYS (S > 100) compared to those for ASNase and CAT (40 < S < 60); nevertheless for all, the native and PEGylated proteins had their biological activity preserved. Envisioning the industrial potential evaluation, an integrated process diagram was defined combining the PEGylation reaction with the purification of the protein conjugates. Two different scenarios were investigated considering the PEGylation reaction performance. For both approaches (complete and incomplete PEGylation reaction), high recovery yields and purities were achieved for the PEGylated conjugates (92.1 ± 0.4% < %RecTCyt-c-PEG < 98.1 ± 0.1%; 84.6% < purity < 100%) and for the unreacted enzyme (%RecBCyt-c = 81 ± 1%; purity = 97.7%), while maintaining their structural integrity.publishe
Improved pharmacokinetics and bone tissue accumulation of Angiotensin-(1–7) peptide through bisphosphonate conjugation
PEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated Attributes
Continuous separation of cytochrome-c PEGylated conjugates by fast centrifugal partition chromatography
Herein, the effective use of aqueous biphasic systems (ABS) in Fast Centrifugal Partition Chromatography (FCPC) for the purification of PEGylated cytochrome c conjugates is shown. High recoveries (between 88% and 100%) and purities (∼100%) were obtained. Both the unreacted cytochrome c and solvents may be recovered and reused, thus allowing the design of a sustainable process in a continuous regime for the isolation of bioconjugates. This process allowed the reduction of the complete E-factor and carbon footprint at circa 100% and 67%, respectively, reinforcing the important environmental contribution of recycling units.publishe